Mednet Logo
CommunityMedical Oncology

What would you offer to a patient with musculoskeletal pain from tarlatamab, requiring hospitalization and opioid use?

The patient is refractory to steroids. Any preferred DMARDs?
Community PollStarted

For steroid-refractory musculoskeletal toxicity from tarlatamab, what is your preferred next-line option?

35 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Answered on

Bone and muscle pain with tarlatamab can be significant (affecting nearly one-third of patients in clinical trials, I think). A multimodal plan combining opioids with non-opioid analgesics, supportive therapies, and proactive side effect monitoring is often necessary to combat this.

The pathway that ...

Join for free or sign in to see the full answer